ReviewEinstein (Sao Paulo, Brazil)2019
Immunoinflammatory mediators in the pathogenesis of diabetes mellitus.
Review in Einstein (Sao Paulo, Brazil), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Association between atherogenic index of plasma and risk of type 2 diabetes mellitus and the mediating effect of BMI: a comparative analysis in Chinese and Japanese populations.Diabetology & metabolic syndrome · 2025Article
- The U-shaped association of fasting plasma glucose to HbA1c ratio with mortality in diabetic and prediabetic populations: the mediating role of systemic immune-inflammation index.Frontiers in endocrinology · 2025Article
- Accuracy of radiographic pixel linear analysis in detecting bone loss in periodontal disease: Study in diabetic rats.The Saudi dental journal · 2021Article
- Association of IL-16 rs11556218 T/G polymorphism with the risk of developing type 2 diabetes mellitus.Journal of diabetes and metabolic disorders · 2021Article
- Inverse relationship between serum adenosine deaminase levels and islet beta cell function in patients with type 2 diabetes.Diabetology & metabolic syndrome · 2021Article
- Mitochondrial dysfunction and pancreatic islet β-cell failure (Review).Experimental and therapeutic medicine · 2020Review
- Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments.Frontiers in endocrinology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Characterized as a metabolic syndrome with multiple consequences for the lives of patients, diabetes mellitus is also classified as a chronic non-communicable disease of great scope in the world. It is a complex disease, with different points of view, including the relation between inflammatory process, obesity and insulin resistance due to the performance of the various immunoinflammatory mediators - called adipokines - on glycemic homeostasis. Recent studies have precisely addressed this aspect for the development of drugs that assist in the protection of pancreatic ß cells from the damages arising from oxidative stress and inflammatory process, in order to control the hyperglycemic picture, which is characteristic of diabetes mellitus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.